

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

Claims 1-11 (Canceled).

Claim 12 (Currently Amended): A parenteral formulation which comprises rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779), an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant.

Claim 13 (Original): The formulation according to claim 12, wherein the alcoholic solvent is ethanol, propylene glycol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, or polyethylene glycol 1000.

Claim 14 (Original): The formulation according to claim 12, wherein the antioxidant is citric acid, glycine, d,l- $\alpha$ -tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, or propyl gallate.

Claim 15 (Original): The formulation according to claim 12, wherein the diluent solvent is water, ethanol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 1000, or propylene glycol.

Claim 16 (Previously Presented): The formulation according to claim 12, wherein the surfactant is polysorbate 20, polysorbate 80, a bile acid, lecithin, an ethoxylated vegetable oil, vitamin E, or polyoxyethylene-polyoxypropylene block copolymers.

Claim 17 (Previously Presented): The formulation according to claim 12, wherein the formulation comprises a concentration of CCI-779 from about 1 mg/mL to about 25 mg/mL.

Claim 18 (Previously Presented): The formulation according to claim 12, wherein the formulation comprises a concentration of CCI-779 from about 2.5 mg/mL to about 10 mg/mL.

Claim 19 (Previously Presented): The formulation according to claim 12, wherein the formulation comprises a concentration of antioxidant from about 0.0005 to 0.5% w/v.

Claim 20 (Previously Presented): The formulation according to claim 12, wherein the formulation comprises a concentration of surfactant from about 0.5% to about 10% w/v.

Claim 21 (Previously Presented): The formulation according to claim 12, wherein the formulation comprises a concentration of alcoholic solvent from about 10% to about 90% w/v.

Claims 22 – 30. cancelled.

31 (Currently Amended). A parenteral formulation which comprises  
about 1 mg/mL to about 25 mg/mL rapamycin 42-ester with 3-  
hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779),  
about 10% to about 90% w/v an alcoholic solvent,  
0.001% to 0.5 % w/v of an antioxidant,  
a diluent solvent, and  
about 0.5% to about 10% w/v surfactant.

32 (Previously Presented). The parenteral formulation according to claim 31, wherein the antioxidant is citric acid and the alcoholic solvent is ethanol.

33 (Previously Presented). The parenteral formulation according to claim 31, comprising ethanol, citric acid, Vitamin E and propylene glycol.

34 (Previously Presented). The parenteral formulation according to claim 33, wherein the antioxidant is d,l- $\alpha$ -tocopherol.

35 (Previously Presented). The parenteral formulation according to claim 31, wherein the antioxidant is citric acid is present in an amount of 0.01% w/v.

36 (Previously Presented). The parenteral formulation according to claim 31, wherein the antioxidant is a mixture of citric acid and d,l- $\alpha$ -tocopherol.

37 (Previously Presented). The parenteral formulation according to claim 31, wherein the surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, PEG-35 castor oil, or mixtures thereof.